RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained an Outperform rating on Ionis Pharmaceuticals (NASDAQ:IONS) and increased the price target from $65 to $70.
January 26, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals' Outperform rating is maintained by RBC Capital, with a raised price target from $65 to $70, indicating a positive outlook.
The increase in price target by RBC Capital suggests a positive outlook on Ionis Pharmaceuticals, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100